782 active trials 296 recruiting 97 Phase 3 48 disease areas 146 changes in 30 days
75 trials changed in the last 30 days: 1 stopped, 30 with notable changes, 44 with minor changes only.
Recruitment suspended
Sponsor's reason: Placed on hold to conduct a review of events on study.
National Cancer Institute (NCI)Phase 1 NCT07055477 Registry history of NCT07055477 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from May 1, 2027 to Jul 1, 2028
Also in this update: Completion pushed from Mar 1, 2028 to May 1, 2029; Interventions modified
National Cancer Institute (NCI)Phase 1 NCT05630794 Registry history of NCT05630794 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2030
National Cancer Institute (NCI)Phase 2 NCT05554419 Registry history of NCT05554419 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jan 1, 2027 to Jan 31, 2030
National Cancer Institute (NCI)Phase 3 NCT03811015 Registry history of NCT03811015 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2029
National Cancer Institute (NCI)Phase 3 NCT04181060 Registry history of NCT04181060 on ClinicalTrials.gov (opens the registry)
Changed
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
National Cancer Institute (NCI)Phase 2 NCT04751370 Registry history of NCT04751370 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
National Cancer Institute (NCI)Phase 1/2 NCT01896999 Registry history of NCT01896999 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Sep 1, 2026 to Jan 1, 2030
Also in this update: Enrollment closed, study ongoing; Completion pushed from Jan 30, 2027 to Feb 1, 2030
National Cancer Institute (NCI)Not specified NCT06744283 Registry history of NCT06744283 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Oct 30, 2026 to Sep 8, 2028
Also in this update: Recruitment opened
National Cancer Institute (NCI)Phase 1/2 NCT07619521 Registry history of NCT07619521 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 30, 2026 to Aug 28, 2029
Also in this update: Recruitment opened
National Cancer Institute (NCI)Phase 2 NCT07551596 Registry history of NCT07551596 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 1, 2026 to Jun 1, 2027
National Cancer Institute (NCI)Phase 1 NCT05627245 Registry history of NCT05627245 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Enrollment increased: 1 → 5 participants; Results posted: Oct 6, 2026
National Cancer Institute (NCI)Phase 1 NCT05413304 Registry history of NCT05413304 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 1 → 5
National Cancer Institute (NCI)Phase 1 NCT04533750 Registry history of NCT04533750 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
National Cancer Institute (NCI)Phase 4 NCT07706673 Registry history of NCT07706673 on ClinicalTrials.gov (opens the registry)
Updated
Phase changed: not applicable → not specified
Also in this update: Final enrollment: 4 participants — 5% of the 80 planned; Trial completed
National Cancer Institute (NCI)Not specified NCT07374692 Registry history of NCT07374692 on ClinicalTrials.gov (opens the registry)
Updated
Trial status changed: Suspended → Active, Not Recruiting
National Cancer Institute (NCI)Phase 1/2 NCT04071236 Registry history of NCT04071236 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
National Cancer Institute (NCI)Phase 1 NCT07672483 Registry history of NCT07672483 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment resumed after suspension
National Cancer Institute (NCI)Phase 1 NCT07388563 Registry history of NCT07388563 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment resumed after suspension
Also in this update: Trial sites expanded: 255 → 261 locations
National Cancer Institute (NCI)Phase 2/3 NCT05058651 Registry history of NCT05058651 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
National Cancer Institute (NCI)Phase 3 NCT05256225 Registry history of NCT05256225 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 35 participants (planned 222)
National Cancer Institute (NCI)Not applicable NCT05605574 Registry history of NCT05605574 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Completion moved earlier from Dec 31, 2027 to Dec 31, 2026
National Cancer Institute (NCI)Phase 2 NCT05327010 Registry history of NCT05327010 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Nov 30, 2026 to May 6, 2025
National Cancer Institute (NCI)Phase 1/2 NCT04708470 Registry history of NCT04708470 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 105 participants (planned 259)
National Cancer Institute (NCI)Not specified NCT01660984 Registry history of NCT01660984 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to May 31, 2027
National Cancer Institute (NCI)Phase 3 NCT02595944 Registry history of NCT02595944 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Mar 31, 2027
National Cancer Institute (NCI)Phase 2 NCT04310007 Registry history of NCT04310007 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Oct 1, 2026 to Feb 4, 2027
National Cancer Institute (NCI)Phase 2 NCT04577755 Registry history of NCT04577755 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 31, 2026 to Sep 30, 2026
National Cancer Institute (NCI)Phase 4 NCT05237947 Registry history of NCT05237947 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 100 → 120 participants
National Cancer Institute (NCI)Phase 1 NCT06885697 Registry history of NCT06885697 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 28 → 40 participants
National Cancer Institute (NCI)Phase 2 NCT05907759 Registry history of NCT05907759 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 198 → 203 locations
And 2 more changes in the last 30 days
National Cancer Institute (NCI)Phase 3 NCT07391774 Registry history of NCT07391774 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 83 → 96 locations
And 2 more changes in the last 30 days
National Cancer Institute (NCI)Phase 3 NCT07388524 Registry history of NCT07388524 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 294 → 302 locations
And 2 more changes in the last 30 days
National Cancer Institute (NCI)Phase 3 NCT07198074 Registry history of NCT07198074 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 68 → 71 locations
And 2 more changes in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT06917911 Registry history of NCT06917911 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 14 → 18 locations
National Cancer Institute (NCI)Phase 2 NCT07281417 Registry history of NCT07281417 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 34 → 37 locations
And 2 more changes in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT07437950 Registry history of NCT07437950 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 142 → 145 locations
National Cancer Institute (NCI)Phase 2 NCT06770582 Registry history of NCT06770582 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 257 → 260 locations
National Cancer Institute (NCI)Phase 3 NCT06422806 Registry history of NCT06422806 on ClinicalTrials.gov (opens the registry)
Changed
Trial sites expanded: 327 → 332 locations
National Cancer Institute (NCI)Phase 3 NCT07061977 Registry history of NCT07061977 on ClinicalTrials.gov (opens the registry)
Changed
Trial sites expanded: 276 → 282 locations
National Cancer Institute (NCI)Phase 3 NCT06337318 Registry history of NCT06337318 on ClinicalTrials.gov (opens the registry)
Changed
Trial sites expanded: 409 → 414 locations
National Cancer Institute (NCI)Phase 3 NCT05675410 Registry history of NCT05675410 on ClinicalTrials.gov (opens the registry)
Changed
Trial sites expanded: 104 → 113 locations
And 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT06649812 Registry history of NCT06649812 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 2 → 7 locations
National Cancer Institute (NCI)Phase 2 NCT07605416 Registry history of NCT07605416 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 165 → 177 locations
National Cancer Institute (NCI)Phase 2 NCT07061964 Registry history of NCT07061964 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 138 → 143 locations
National Cancer Institute (NCI)Phase 2 NCT04840602 Registry history of NCT04840602 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 17, 2026 to Sep 16, 2027
National Cancer Institute (NCI)Phase 3 NCT02306161 Registry history of NCT02306161 on ClinicalTrials.gov (opens the registry)
Updated
Final enrollment: 68 participants (planned 88)
Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Jul 16, 2025; Completion pushed from Oct 1, 2026 to Oct 5, 2027
National Cancer Institute (NCI)Phase 2 NCT04548752 Registry history of NCT04548752 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 10, 2026 to Sep 10, 2027
National Cancer Institute (NCI)Phase 2 NCT01841736 Registry history of NCT01841736 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Also in this update: Trial arms changed: 39 → 41; and 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT05564390 Registry history of NCT05564390 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Aug 19, 2026 to Sep 1, 2027
National Cancer Institute (NCI)Phase 3 NCT03375320 Registry history of NCT03375320 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Oct 31, 2026 to Sep 3, 2027
National Cancer Institute (NCI)Phase 2 NCT04175912 Registry history of NCT04175912 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 11, 2026 to Sep 30, 2027
National Cancer Institute (NCI)Phase 2 NCT02883062 Registry history of NCT02883062 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Sep 1, 2026 to Jul 30, 2026
Also in this update: Completion pushed from Dec 1, 2027 to Jun 15, 2028
National Cancer Institute (NCI)Phase 1 NCT02203526 Registry history of NCT02203526 on ClinicalTrials.gov (opens the registry)
Updated
Final enrollment: 98 participants (planned 134)
Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Jul 27, 2026; Completion pushed from Oct 1, 2026 to Sep 24, 2027
National Cancer Institute (NCI)Phase 2 NCT04071223 Registry history of NCT04071223 on ClinicalTrials.gov (opens the registry)
Updated
Final enrollment: 58 participants (planned 70)
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Apr 15, 2026; Completion pushed from Sep 30, 2026 to Sep 23, 2027
National Cancer Institute (NCI)Phase 2 NCT06169215 Registry history of NCT06169215 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Aug 19, 2026 to Sep 2, 2027
National Cancer Institute (NCI)Phase 2 NCT04079712 Registry history of NCT04079712 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
National Cancer Institute (NCI)Phase 2 NCT05001880 Registry history of NCT05001880 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 4, 2026 to Aug 20, 2027
National Cancer Institute (NCI)Phase 2 NCT04729959 Registry history of NCT04729959 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Oct 8, 2026 to Sep 23, 2027
National Cancer Institute (NCI)Phase 1 NCT02015117 Registry history of NCT02015117 on ClinicalTrials.gov (opens the registry)
Updated
Final enrollment: 23 participants (planned 40)
Also in this update: Primary completion date changed from estimate of Dec 1, 2026 to Dec 10, 2024; Completion pushed from Dec 1, 2026 to Sep 18, 2027; and 2 more changes in the last 30 days
National Cancer Institute (NCI)Phase 1 NCT03528642 Registry history of NCT03528642 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 17, 2026 to Sep 11, 2027
National Cancer Institute (NCI)Phase 1 NCT01303341 Registry history of NCT01303341 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 17, 2026 to Sep 11, 2027
National Cancer Institute (NCI)Phase 1 NCT02453620 Registry history of NCT02453620 on ClinicalTrials.gov (opens the registry)
Updated
Final enrollment: 7458 participants (planned 8300)
Also in this update: Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025; Completion pushed from Sep 28, 2026 to Sep 21, 2027
National Cancer Institute (NCI)Not applicable NCT02194738 Registry history of NCT02194738 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-07 | NCT07862517 Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and… | Phase 2 | Not Yet Recruiting |
| Early Phase 1 | 1 | |
| Phase 1 | 164 | |
| Phase 1/2 | 78 | |
| Phase 2 | 315 | |
| Phase 2/3 | 17 | |
| Phase 3 | 80 | |
| Phase 4 | 3 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07706673 | ESCUDDO Long Term Follow Up | Human Papillomavirus Infection | Enrolling by Invitation | 2026-09-22 |
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in… | Human Papillomavirus-Related Cervical Carcinoma | Active, Not Recruiting | 2026-09-21 |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of… | Human Papillomavirus Infection | Active, Not Recruiting | 2025-09-04 |
| Phase 3 | ||||
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With… | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recruiting | 2026-10-09 |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… | Chronic Lymphocytic Leukemia | Recruiting | 2026-10-09 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs… | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Recruiting | 2026-10-09 |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting | 2026-10-09 |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden… | Classic Follicular Lymphoma | Recruiting | 2026-10-09 |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment… | Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | 2026-10-09 |
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… | Locally Advanced Cervical Adenocarcinoma | Recruiting | 2026-10-09 |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin… | Advanced Endometrial Carcinoma | Recruiting | 2026-10-09 |
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early… | Lung Non-Small Cell Carcinoma | Recruiting | 2026-10-09 |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy… | Lung Non-Small Cell Carcinoma | Recruiting | 2026-10-08 |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With… | Advanced Lung Non-Small Cell Carcinoma | Recruiting | 2026-10-08 |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of… | Ganglioneuroblastoma, Nodular | Recruiting | 2026-10-08 |
| NCT06422806 | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for… | Metastatic Dedifferentiated Liposarcoma | Recruiting | 2026-10-07 |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard… | Lung Non-Small Cell Carcinoma | Recruiting | 2026-10-07 |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting | 2026-10-07 |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus… | Locally Advanced Urothelial Carcinoma | Recruiting | 2026-10-05 |
| NCT04166409 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With… | Low Grade Astrocytoma | Recruiting | 2026-09-11 |
| NCT02306161 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly… | Metastatic Ewing Sarcoma | Active, Not Recruiting | 2026-10-06 |
| NCT04214262 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for… | Lung Non-Small Cell Carcinoma | Active, Not Recruiting | 2026-10-06 |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2… | Endometrial Carcinoma | Active, Not Recruiting | 2026-10-02 |
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have… | Breast Adenocarcinoma | Active, Not Recruiting | 2026-10-01 |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab… | Breast Adenocarcinoma | Active, Not Recruiting | 2026-10-01 |
Leukemia (92) · Sarcoma (63) · Breast Cancer (57) · Lung Cancer (57) · Multiple Myeloma (50) · Non-Hodgkin Lymphoma (49) · Ovarian Cancer (48) · Non-Small Cell Lung Cancer (NSCLC) (46) · Colorectal Cancer (41) · Prostate Cancer (41)